دورية أكاديمية
MDA5-autoimmunity and interstitial pneumonitis contemporaneous with the COVID-19 pandemic (MIP-C).
| العنوان: | MDA5-autoimmunity and interstitial pneumonitis contemporaneous with the COVID-19 pandemic (MIP-C). |
|---|---|
| المؤلفون: | David P; Leeds Teaching Hospitals NHS Trust, Rheumatology Department, Leeds, United Kingdom; University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom; Internal Medicine B, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel., Sinha S; Department of Cellular and Molecular Medicine, School of Medicine, University of California San Diego, La Jolla, CA, 92093, USA., Iqbal K; Leeds Teaching Hospitals NHS Trust, Rheumatology Department, Leeds, United Kingdom., De Marco G; University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom; Mid Yorkshire Teaching NHS Trust, Rheumatology, Wakefield, United Kingdom; NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom., Taheri S; Department of Computer Science and Engineering, Jacob's School of Engineering, University of California San Diego, La Jolla, CA, 92093, USA., McLaren E; Department of Cellular and Molecular Medicine, School of Medicine, University of California San Diego, La Jolla, CA, 92093, USA., Maisuria S; Leeds Teaching Hospitals NHS Trust, Pathology, Leeds, United Kingdom., Arumugakani G; Leeds Teaching Hospitals NHS Trust, Pathology, Leeds, United Kingdom; University of Leeds, Immunology, Leeds, United Kingdom., Ash Z; Bradford Teaching Hospitals NHS Foundation Trust, Rheumatology, Bradford, United Kingdom., Buckley C; Leeds Teaching Hospitals NHS Trust, Rheumatology Department, Leeds, United Kingdom., Coles L; Leeds Teaching Hospitals NHS Trust, Rheumatology Department, Leeds, United Kingdom., Hettiarachchi C; Mid Yorkshire Teaching NHS Trust, Rheumatology, Wakefield, United Kingdom., Payne E; Leeds Teaching Hospitals NHS Trust, Pathology, Leeds, United Kingdom., Savic S; University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom; NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom; Department of Clinical Immunology and Allergy, Leeds Teaching Hospitals, NHS Trust, Leeds, UK., Smithson G; Mid Yorkshire Teaching NHS Trust, Rheumatology, Wakefield, United Kingdom., Slade M; Mid Yorkshire Teaching NHS Trust, Rheumatology, Wakefield, United Kingdom., Shah R; Leeds Teaching Hospitals NHS Trust, Rheumatology Department, Leeds, United Kingdom., Marzo-Ortega H; Leeds Teaching Hospitals NHS Trust, Rheumatology Department, Leeds, United Kingdom; University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom; NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom., Keen M; Bradford Teaching Hospitals NHS Foundation Trust, Rheumatology, Bradford, United Kingdom., Lawson C; Harrogate and District NHS Foundation Trust, Rheumatology, Harrogate, United Kingdom., Mclorinan J; Leeds Teaching Hospitals NHS Trust, Rheumatology Department, Leeds, United Kingdom., Nizam S; Mid Yorkshire Teaching NHS Trust, Rheumatology, Wakefield, United Kingdom., Reddy H; Airedale NHS Foundation Trust, Rheumatology, Steeton with Eastburn, United Kingdom., Sharif O; Calderdale and Huddersfield NHS Foundation Trust, Rheumatology, Huddersfield and Halifax, United Kingdom., Sultan S; Airedale NHS Foundation Trust, Rheumatology, Steeton with Eastburn, United Kingdom., Tran G; Harrogate and District NHS Foundation Trust, Rheumatology, Harrogate, United Kingdom., Wood M; Leeds Teaching Hospitals NHS Trust, Rheumatology Department, Leeds, United Kingdom., Wood S; Leeds Teaching Hospitals NHS Trust, Rheumatology Department, Leeds, United Kingdom., Ghosh P; Department of Cellular and Molecular Medicine, School of Medicine, University of California San Diego, La Jolla, CA, 92093, USA; Department of Medicine, School of Medicine, and Veterans Affairs Medical Center, University of University of California San Diego, La Jolla, CA, 92093, USA. Electronic address: prghosh@ucsd.edu., McGonagle D; Leeds Teaching Hospitals NHS Trust, Rheumatology Department, Leeds, United Kingdom; University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom. Electronic address: d.g.mcgonagle@leeds.ac.uk. |
| المصدر: | EBioMedicine [EBioMedicine] 2024 Jun; Vol. 104, pp. 105136. Date of Electronic Publication: 2024 May 08. |
| نوع المنشور: | Journal Article; Observational Study |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101647039 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2352-3964 (Electronic) Linking ISSN: 23523964 NLM ISO Abbreviation: EBioMedicine Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [Amsterdam] : Elsevier B.V., [2014]- |
| مواضيع طبية MeSH: | COVID-19*/immunology , Interferon-Induced Helicase, IFIH1*/genetics , Interferon-Induced Helicase, IFIH1*/immunology , Lung Diseases, Interstitial*/immunology , Lung Diseases, Interstitial*/genetics , SARS-CoV-2*/immunology , Autoimmunity* , Autoantibodies*/immunology, Humans ; Male ; Female ; Middle Aged ; Aged ; Retrospective Studies ; Pandemics ; Dermatomyositis/immunology ; Dermatomyositis/genetics ; Adult |
| مستخلص: | Background: Anti-MDA5 (Melanoma differentiation-associated protein-5) positive dermatomyositis (MDA5 + -DM) is characterised by rapidly progressive interstitial lung disease (ILD) and high mortality. MDA5 is an RNA sensor and a key pattern recognition receptor for the SARS-CoV-2 virus. Methods: This is a retrospective observational study of a surge in MDA5 autoimmunity, as determined using a 15 muscle-specific autoantibodies (MSAs) panel, between Janurary 2018 and December 2022 in Yorkshire, UK. MDA5-positivity was correlated with clinical features and outcome, and regional SARS-CoV-2 positivity and vaccination rates. Gene expression patterns in COVID-19 were compared with autoimmune lung disease and idiopathic pulmonary fibrosis (IPF) to gain clues into the genesis of the observed MDA5 + -DM outbreak. Findings: Sixty new anti-MDA5+, but not other MSAs surged between 2020 and 2022, increasing from 0.4% in 2019 to 2.1% (2020), 4.8% (2021) and 1.7% (2022). Few (8/60) had a prior history of confirmed COVID-19, peak rates overlapped with regional SARS-COV-2 community positivity rates in 2021, and 58% (35/60) had received anti-SARS-CoV-2 vaccines. 25/60 cases developed ILD which rapidly progression with death in 8 cases. Among the 35/60 non-ILD cases, 14 had myositis, 17 Raynaud phenomena and 10 had dermatomyositis spectrum rashes. Transcriptomic studies showed strong IFIH1 (gene encoding for MDA5) induction in COVID-19 and autoimmune-ILD, but not IPF, and IFIH1 strongly correlated with an IL-15-centric type-1 interferon response and an activated CD8+ T cell signature that is an immunologic hallmark of progressive ILD in the setting of systemic autoimmune rheumatic diseases. The IFIH1 rs1990760TT variant blunted such response. Interpretation: A distinct pattern of MDA5-autoimmunity cases surged contemporaneously with circulation of the SARS-COV-2 virus during COVID-19. Bioinformatic insights suggest a shared immunopathology with known autoimmune lung disease mechanisms. Funding: This work was supported in part by the National Institute for Health Research (NIHR) Leeds Biomedical Research Centre (BRC), and in part by the National Institutes of Health (NIH) grant R01-AI155696 and pilot awards from the UC Office of the President (UCOP)-RGPO (R00RG2628, R00RG2642 and R01RG3780) to P.G. S.S was supported in part by R01-AI141630 (to P.G) and in part through funds from the American Association of Immunologists (AAI) Intersect Fellowship Program for Computational Scientists and Immunologists. Competing Interests: Declaration of interests The authors declare that they have no financial conflict of interests for this study. (Copyright © 2024. Published by Elsevier B.V.) |
| التعليقات: | Update of: medRxiv. 2023 Nov 05:2023.11.03.23297727. doi: 10.1101/2023.11.03.23297727. (PMID: 37961408) |
| معلومات مُعتمدة: | R01 AI155696 United States AI NIAID NIH HHS |
| فهرسة مساهمة: | Keywords: Autoimmune Raynauds; Autoimmune rashes; Coronavirus-19 (Covid-19); Interstitial lung disease (ILD); MDA5-autoimmunity and interstitial pneumonitis contemporaneous with the COVID-19 (MIP-C); Melanoma differentiation-associated protein-5 (MDA5) |
| المشرفين على المادة: | EC 3.6.4.13 (Interferon-Induced Helicase, IFIH1) EC 3.6.1.- (IFIH1 protein, human) 0 (Autoantibodies) |
| تواريخ الأحداث: | Date Created: 20240509 Date Completed: 20240616 Latest Revision: 20240705 |
| رمز التحديث: | 20240705 |
| مُعرف محوري في PubMed: | PMC11090026 |
| DOI: | 10.1016/j.ebiom.2024.105136 |
| PMID: | 38723554 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder كن أول من يترك تعليقا!